ROR1 and B-cell chronic lymphocytic leukemia: Anti-ROR1 monoclonal antibody cirmtuzumab (UC-961) has completed a phase 1 clinical trial for CLL with encouraging results, as demonstrated by the inhibition of Wnt5a/ROR1 signaling in ROR1-positive leukemic cells, and a phase 1b/2 combination clinical trial has been initiated for patients with CLL and MCL [38].